title: Clinical usefulness of drug-eluting stents in the treatment of dialysis patients with coronary artery disease.
abstract: OBJECTIVE
  To investigate the clinical outcomes of paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) in patients on dialysis.
  
  
  RESULTS
  Between May 2004 and December 2008, 95 patients on dialysis with 124 lesions were treated with PES alone, and were compared to 184 patients on dialysis with 244 lesions treated with SES alone, retrospectively. One-year major adverse cardiac event (MACE) including stent thrombosis, target lesion revascularisation (TLR), myocardial infarction (MI) and cardiac death were compared. Baseline characteristics were similar except for previous CABG (p = 0.02) and reference vessel diameter (p = 0.04). During hospitalisation, all cause death was more frequently observed in the PES group (p = 0.004). In-hospital MACE was not significantly different (p = 0.8). The incidence of 1-year MACE in the PES group was lower than that in the SES group (14.7%, 28.3%, p = 0.04), mainly due to the reduction of TLR (11.6%, 25.0%, p = 0.03). Rates of stent thrombosis (0%, 2.7%, p = 0.1), MI (1.1%, 3.8%, p = 0.2), and cardiac death (3.2%, 4.4%, p = 0.6) were not significantly different.
  
  
  CONCLUSIONS
  PES appears to be more efficient in reducing angiographic and clinical restenosis in dialysis patients compared with SES.
authors.affiliation: Division of Cardiology, Cardiovascular Center, Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan. Masaya.Otsuka@ma7.seikyo.ne.jp
authors.forename: Masaya
authors.initials: M
authors.lastname: Otsuka
authors.forename: Mamoru
authors.initials: M
authors.lastname: Toyofuku
authors.forename: Noriaki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Chikaaki
authors.initials: C
authors.lastname: Motoda
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Kawase
authors.forename: Ryo
authors.initials: R
authors.lastname: Takeda
authors.forename: Shinji
authors.initials: S
authors.lastname: Mito
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Tamekiyo
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Okimoto
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Hirao
authors.forename: Yuji
authors.initials: Y
authors.lastname: Muraoka
authors.forename: Hironori
authors.initials: H
authors.lastname: Ueda
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Masaoka
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology; D054855:Drug-Eluting Stents; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D017239:Paclitaxel / Q000008:administration & dosage; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D006435:Renal Dialysis / Q000009:adverse effects / Q000401:mortality; D051437:Renal Insufficiency / Q000150:complications / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel; D020123:Sirolimus